ETANA: LOCAL VACCINE PRODUCTION TO ACHIEVE NATIONAL PHARMACEUTICAL INDEPENDENCE AND GLOBAL EXPANSION

Jakarta, 25 January 2025 – PT Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to supporting government programs aimed at strengthening domestic vaccine production as part of efforts to achieve national health resilience and independence. This commitment was demonstrated in 2024 through Etana’s achievement in obtaining Good Manufacturing Practices (CPOB) certification and a Marketing Authorization (NIE) for its PCV-13 vaccine product, which has now been included in the national routine immunization program.

“As a national biotechnology company, Etana is proud to have earned the government’s trust to supply PCV-13 vaccines for the routine immunization program. With this support, we are even more motivated to continue innovating and developing other biotechnology products and vaccines that benefit society,” said Indra Lamora, Director of the Anti-Infectious Business Unit at Etana.

The PCV-13 vaccine, locally produced by Etana, is expected to provide a safe, affordable, and high-quality solution for public vaccination needs, while also reducing dependence on imported vaccines.

“By producing locally, Etana is also able to create opportunities to expand access and export this vaccine to ASEAN and OIC countries,” Indra added.

In 2025, Etana has set two main priorities. First, to ensure the availability of domestic production, particularly PCV-13 to support the government’s routine immunization program. Second, to continue the development of innovative domestic vaccines, such as HPV and TB vaccines, which are part of the government’s immunization expansion program.

“These two vaccines are part of the government’s expanded immunization program launched through the Ministry of Health, aimed at eliminating cervical cancer and preventing the transmission of tuberculosis in Indonesia,” Indra said.

Etana is also actively engaging in strategic collaborations to address other pressing health challenges. One of its latest initiatives is the development of a domestic dengue vaccine, in collaboration with the University of Indonesia (UI) and the National Research and Innovation Agency (BRIN), supported by funding from LPDP.

“Dengue fever is a serious public health problem in Indonesia. Addressing this issue requires sustained efforts and collaboration between ministries, agencies, industry, and universities,” Indra noted.

With its vision to act as a catalyst for national healthcare transformation, Etana remains committed to supporting the government in improving public health quality. The company also aims to reduce reliance on imported products while contributing to economic growth.

“We are committed to continuously supporting the government in achieving national health goals. We believe that through collaboration, we can build a stronger healthcare system,” Indra concluded.

About Etana

Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.

Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.